GST rate amendment adds oncology drugs to reduced-rate list and reclassifies extruded savoury products and seats. Amendment to the State GST rate notification adds Trastuzumab Deruxtecan, Osimertinib and Durvalumab to the reduced-rate list; inserts an extruded or expanded savoury product classification into the mid-rate schedule and expands the description of un-fried or un-cooked snack pellets to include extruded or expanded savoury products; and restructures seat tariff entries by substituting a broader seat description and separately listing motor vehicle seats under the higher-rate schedule.
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
GST rate amendment adds oncology drugs to reduced-rate list and reclassifies extruded savoury products and seats.
Amendment to the State GST rate notification adds Trastuzumab Deruxtecan, Osimertinib and Durvalumab to the reduced-rate list; inserts an extruded or expanded savoury product classification into the mid-rate schedule and expands the description of un-fried or un-cooked snack pellets to include extruded or expanded savoury products; and restructures seat tariff entries by substituting a broader seat description and separately listing motor vehicle seats under the higher-rate schedule.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
of 
Join Channel
TaxTMI 
